Corteria: tuning therapies to heart failure subpopulations

With €77 million ($84 million) across seed and series A rounds from investors including Jeito and OrbiMed, Paris-based Corteria is targeting three different heart disease patient subpopulations with two peptide CRHR2 agonists and a mAb that binds circulating vasopressin. The company was founded in 2021 by two former Sanofi executives and pair of programs licensed from the pharma. 

Philippe Janiak, Corteria Pharmaceuticals S.A.S. CEO, told BioCentury that he and CSO Marie-Laure Ozoux co-founded Corteria in 2021 following the discontinuation of cardiovascular drug development by Sanofi (Euronext:SAN; NASDAQ:SNY), where Janiak was head of cardiovascular research and Ozoux was a project leader. ...